Galectin agreement on primary endpoint, Phase 3 for belapectin in MASH cirrhosis, portal hypertension

 

Galectin Therapeutics gains FDA agreement on primary endpoint and Phase 3 pathway for belapectin in MASH cirrhosis and portal hypertension

• Positive FDA Type C meeting established the regulatory framework for belapectin development in MASH cirrhosis and portal hypertension.
• Galectin plans to file the Phase 3 belapectin protocol in Q3 2026.
• The company intends to seek strategic and financial partners to advance the belapectin Phase 3 program.

https://finviz.com/stock?t=GALT&p=d